Name | Number of supported studies | Average coverage | |
---|---|---|---|
B cell | 4 studies | 24% ± 6% | |
memory B cell | 4 studies | 22% ± 2% | |
naive B cell | 4 studies | 23% ± 6% | |
plasmablast | 4 studies | 35% ± 15% |
Insufficient scRNA-seq data for expression of IGKV3-20 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 91% | 2658.81 | 524 / 578 | 82% | 1803.82 | 949 / 1155 |
stomach | 72% | 3207.76 | 260 / 359 | 63% | 1013.58 | 179 / 286 |
intestine | 56% | 7061.98 | 539 / 966 | 57% | 670.31 | 301 / 527 |
breast | 46% | 1702.08 | 212 / 459 | 54% | 808.17 | 600 / 1118 |
spleen | 100% | 25047.06 | 240 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 83% | 3794.84 | 773 / 929 | 0% | 0 | 0 / 0 |
bladder | 29% | 1096.19 | 6 / 21 | 50% | 550.61 | 250 / 504 |
tonsil | 0% | 0 | 0 / 0 | 76% | 2104.76 | 34 / 45 |
esophagus | 23% | 404.65 | 330 / 1445 | 48% | 615.29 | 88 / 183 |
pancreas | 11% | 103.36 | 36 / 328 | 58% | 681.73 | 103 / 178 |
liver | 55% | 447.94 | 124 / 226 | 14% | 161.47 | 56 / 406 |
uterus | 24% | 313.30 | 40 / 170 | 43% | 612.95 | 196 / 459 |
thymus | 31% | 2383.29 | 202 / 653 | 33% | 741.63 | 197 / 605 |
kidney | 40% | 1144.88 | 36 / 89 | 22% | 280.40 | 196 / 901 |
ovary | 20% | 222.84 | 36 / 180 | 35% | 687.33 | 152 / 430 |
skin | 3% | 26.05 | 51 / 1809 | 44% | 858.37 | 208 / 472 |
prostate | 33% | 526.13 | 81 / 245 | 11% | 86.85 | 57 / 502 |
adipose | 28% | 671.58 | 337 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 24% | 1017.45 | 7 / 29 |
blood vessel | 22% | 435.38 | 295 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 9% | 125.42 | 23 / 258 | 5% | 77.26 | 12 / 230 |
heart | 5% | 131.87 | 44 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 5% | 116.53 | 4 / 80 |
brain | 0% | 3.19 | 13 / 2642 | 2% | 9.78 | 14 / 705 |
muscle | 1% | 6.86 | 5 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006955 | Biological process | immune response |
GO_0002250 | Biological process | adaptive immune response |
GO_0002377 | Biological process | immunoglobulin production |
GO_0003094 | Biological process | glomerular filtration |
GO_0019731 | Biological process | antibacterial humoral response |
GO_0005615 | Cellular component | extracellular space |
GO_0072562 | Cellular component | blood microparticle |
GO_0070062 | Cellular component | extracellular exosome |
GO_0071756 | Cellular component | pentameric IgM immunoglobulin complex |
GO_0005576 | Cellular component | extracellular region |
GO_0071751 | Cellular component | secretory IgA immunoglobulin complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0071748 | Cellular component | monomeric IgA immunoglobulin complex |
GO_0003823 | Molecular function | antigen binding |
Gene name | IGKV3-20 |
Protein name | Immunoglobulin kappa variable 3-20 (Ig kappa chain V-III region B6) (Ig kappa chain V-III region GOL) (Ig kappa chain V-III region HAH) (Ig kappa chain V-III region HIC) (Ig kappa chain V-III region IARC/BL41) (Ig kappa chain V-III region NG9) (Ig kappa chain V-III region SIE) (Ig kappa chain V-III region Ti) (Ig kappa chain V-III region WOL) |
Synonyms | |
Description | FUNCTION: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition . Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens . The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen . . |
Accessions | P01619 ENST00000492167.1 ENST00000632822.1 |